Zenocutuzumab (MCLA-128) 是一种双特异性人源化 IgG1 抗体，包含两个不同的 Fab 臂，靶向HER2和HER3的细胞外结构域。
| 生物活性 | Zenocutuzumab (MCLA-128) is a bispecific humanizedIgG1antibody containing two different Fab arms, targeting extracellular domains ofHER2andHER3[1]. |
体外研究
(In Vitro) | Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长[1]。
Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物[1]。
Cell Viability Assay[1] | Cell Line: | Human bronchiolar epithelial cell lines (HBEC) | | Concentration: | 0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM | | Incubation Time: | 96 h | | Result: | Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions. |
Western Blot Analysis[1] | Cell Line: | HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells | | Concentration: | 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM | | Incubation Time: | 24 hours | | Result: | Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation. |
|
体内研究
(In Vivo) | Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退[1]。
| Animal Model: | 6 to 12-week-old female NSG(TM) (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1]. | | Dosage: | 2.5 mg/kg, 8 mg/kg, or 25 mg/kg | | Administration: | i.p.; once weekly; for 28 days | | Result: | Blocked growth of lung and ovarian cancer PDX models. |
|
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com